New drug BC006 aims to slow lung scarring in IPF patients
NCT ID NCT07447102
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase II study tests a drug called BC006 in 96 adults with idiopathic pulmonary fibrosis (IPF), a disease that causes lung scarring and breathing difficulty. The trial first checks safety in a small group, then randomly assigns patients to receive BC006 or a placebo every two weeks for 24 weeks. The main goal is to see if BC006 improves lung function (measured by FVC) and is safe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BC006 (a drug given by IV infusion)
What this could lead to
If it works, this could point toward a new treatment to slow lung scarring and improve breathing in people with idiopathic pulmonary fibrosis.
What could go wrong
This is an early Phase II trial with only 96 participants, so results may not apply to everyone. The drug may cause side effects or fail to improve lung function compared to placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS (IPF) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dragonboat Biopharmaceutical,Co.,Ltd
RECRUITINGShanghai, Shanghai Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••